We are live on ! Find out more
BMY.RT

Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT

Delisted

BMY.RT was delisted on the 31st of December, 2020.

Back to rankings

3 hedge funds and large institutions have $4.66M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more capital invested

Capital invested by funds: $3.59M → $4.66M (+$1.06M)

0% more funds holding

Funds holding: 3 → 3 (0)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

BMY.RT Hedge Fund Activity: Q2 2022 in Review

3 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q2 2022, worth a combined $4.66M — up 30% from $3.59M a quarter earlier.

Fund positioning in BMY.RT was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 3 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $4.66M of Bristol-Myers Squibb Company Contingent Value Rights stock for Q2 2022, up 30% quarter-over-quarter.
  • 0 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q2 2022 and 0 closed out.

Based on aggregated 13F filings for Q2 2022.